Business Wire

Defense Innovation Unit (DIU) Selects Immervision InnovationLab to Develop a Computer Vision Wide Angle Camera for the Blue UAS Framework Project

Share

Immervision, the Montreal-based leader in wide-angle intelligent vision, today announced it has received an award from the Defense Innovation Unit (DIU), part of the U.S. Department of Defense (DoD) for a Blue UAS Frameworkeffort.

The Immervision InnovationLab team is developing a wide-angle computer vision camera for small Unmanned Aerial Systems (sUAS), enabling advanced low-light vision for Blue UAS Frameworkeffort which provides affordable, trusted, high performing, and interoperable UAS drone technologies for commercial and defense applications.

“We are honored that the Defense Innovation Unit has chosen Immervision’s InnovationLab to create this innovative wide angle computer vision camera optimized for drones in low light vision and autonomous flight,” said Alessandro Gasparini, Executive Vice President, Operations and Chief Commercial Officer of Immervision. “Immervision’s technology has been widely adopted in aerospace, surveillance systems and for consumer electronics for over 20 years. We look forward to working with the DIU to deliver secured, highly advanced sUAS camera for the U.S. Department of Defense’s applications.”

Immervision has been involved in vision system designs for highly complex applications such as aerospace cameras, stratospheric balloons as well as commercial applications from video surveillance, action cameras, IoT to mobile phones. Immervision’s technology provides wide-angle field with edge-to-edge augmented resolution, controlled distortion, and withstands extreme conditions.

About Immervision

Immervision enables intelligent vision in any device. Our Deep Seeing technology and renowned experts in wide-angle optical design and image processing enable smart devices with superhuman eyes to capture high quality visual and contextual data. We invent, customize and license wide-angle lenses and imaging software technology for AI, machine vision and user applications, from capture to display, in the mobile, automotive, robotics, security, and other industrial and consumer product industries. www.immervision.com

Contact information

Immervision
Manuel Magini
Director, Marketing and Communications
C: +1 (514) 294-5526
manuel.magini@immervision.com

US Press Contact
Nicole Conley
Nicole.conley@taniscomm.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GPD Companies, Inc. to Acquire Distrupol22.1.2021 14:33:00 CETPress release

GPD Companies, Inc., an affiliate of One Rock Capital Partners, LLC (“One Rock”), today announced that it has entered into a definitive agreement to acquire Distrupol, a subsidiary of Univar Solutions Inc. (NYSE: UNVR) and a leading European distributor of thermoplastics to the polymer processing industry. Terms of the transaction, which is expected to close in the first half of 2021, were not disclosed. Headquartered in Surrey, England, with broad geographic reach across Europe, Distrupol has provided value-added sales and application development of thermoplastic resins for over 50 years. Through its decades-long relationships with world class supply partners, the company offers a robust array of superior performance products and solutions that meet the needs of diverse end users from leading and emerging industries, such as the consumer, medical, automotive, and electrical sectors, among others. Distrupol caters to over 1,300 customers across 13 countries with a portfolio of over 4,0

Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results22.1.2021 12:50:00 CETPress release

Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2020. Fourth-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeDec. 31, 2020Sept. 30, 2020Dec. 31, 2019SequentialYear-on-yearRevenue $5,532 $5,258 $8,228 5% -33%Income (loss) before taxes - GAAP basis $471 $(54) $452 n/m 4%Net income (loss) - GAAP basis $374 $(82) $333 n/m 12%Diluted EPS (loss per share) - GAAP basis $0.27 $(0.06) $0.24 n/m 12% Adjusted EBITDA* $1,112 $1,018 $1,648 9% -33%Adjusted EBITDA margin* 20.1% 19.4% 20.0% 73 bps 6 bpsPretax segment operating income* $654 $575 $1,006 14% -35%Pretax segment operating margin* 11.8% 10.9% 12.2% 90 bps -40 bpsNet income, excluding charges & credits* $309 $228 $545 35% -43%Diluted EPS, excluding charges & credits* $0.22 $0.16 $0.39 37% -44% Revenue by Geography International $4,343 $4,210 $5,834 3% -26%North America 1,167 1,034 2,339 13% -50%Other 22 14 55 n/m n/m $5,532 $5,258 $8,228 5% -33% *These are non-

JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)22.1.2021 07:00:00 CETPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images". This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005316/en/ Cold Field Emission Cryo-Electron Microscope CRYO ARM(TM) 300 II (JEM-3300) (Photo: Business Wire) Development Background Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class res

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment21.1.2021 23:12:00 CETPress release

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines — ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine— dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.1 Lynn Baxter, Head of North America, ViiV He

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)21.1.2021 22:30:00 CETPress release

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The BLA submission is based on data from the Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy. The trial enrolled 94 patients, including several with well-controlled human immunodeficiency virus (HIV) infection. The study, which was recently presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, resulted in an objective response rate (ORR) of 14% for retifanlimab monotherapy as determined by inde

Wistron and Kalray Announce FURIO1200™ Storage Appliance21.1.2021 17:45:00 CETPress release

Wistron, a leader in ICT (Information and communications technology) products, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider in new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, announce the availability of FURIO1200™, a 24-Flash-Drive NVMe-oF based storage node appliance, integrating Kalray’s NVMe-oF K200™ smart storage adapter, powered by its MPPA® Coolidge™ intelligent processor, and Wistron LYMMA chassis. FURIO1200™ is a new type of hyper-fast disaggregated storage solution delivering ultra-high throughput and reliability. It is the ideal solution for Cloud Service Providers and Enterprises running applications with intensive AI and Data Analytics workloads as well as to optimize their next generation storage. Data Centers are undergoing a very important revolution due to the explosion of usages, the surge of data to be processed and the exponential growth of the number of machines to be managed to support this

NumAlim Selects Dawex and Orange Business Services for its Data and Services Exchange Platform21.1.2021 17:40:00 CETPress release

NumAlim announced an agreement with Dawex, the leader in Data Exchange technology, and Orange Business Services, a network-native digital services company, to deploy its agri-food digital exchange platform. By relying on these two leading players, NumAlim chose secure technological solutions guaranteeing the sovereignty of French food data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005722/en/ (Photo: Dawex) As early as Q1 2021, the NumAlim data and services exchange "Hub" will offer 18,000 companies in the food industry the opportunity to valorize, acquire and enrich all types of data: production, consumption, traceability, consumer opinions and research, as well as a wide range of services based on data (trend analysis, reformulation, regulatory watch…). "NumAlim is the answer to the needs for transparency, value creation and trust expressed by the food industry, consumers, and public authorities.” says Jérôme Fr